CDK4/6 inhibitors Archives - Drugs in Context

Home CDK4/6 inhibitors

Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR+/HER2– breast cancer treated with CDK4/6 inhibitors and endocrine therapy

Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti

Article Type

Original Research

Published

20 Jun 2023

This real-life study investigated the link between clinical complexity and quality of life of patients with HR+/HER2– advanced breast cancer treated with CDK4/6 inhibitors.

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Federico Sottotetti, Elisa Ferraris, Barbara Tagliaferri, Raffaella Palumbo, Erica Quaquarini, Cristina Teragni, Emanuela Balletti, Claudia Leli, Andrea Premoli, Ludovica Mollica, Silvia Puglisi, Silvia Sardi, Alberto Malovini, Paolo Pedrazzoli, Antonio Bernardo

Article Type

Original Research

Published

05 Sep 2022

In this real-life study, the authors aim to evaluate the prognostic role of variations in cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) levels in patients with HR+/HER2− breast cancer treated with CDK4/6 inhibitors. The goal of this investigation is to consider whether it would be possible to use these markers as a monitoring tool to diagnose earlier, faster and in a more practical way.